SEC Form 4 · accession 0001209191-16-135653

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Aug 3, 2016

Accepted (ET)

Aug 5, 2016 · 1:01 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Aug 3, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Aug 3, 2016	S	3,300	$100.09	D	271,425	D
Common Stock^F2,F4	Aug 3, 2016	S	3,200	$100.74	D	268,225	D
Common Stock^F2,F5	Aug 3, 2016	S	30,500	$100.55	D	92,200	I	Common Stock Held In Trust
Common Stock^F2,F6	Aug 3, 2016	S	10,000	$101.17	D	82,200	I	Common Stock Held In Trust
Common Stock	holding	—	—		—	13,286	I	401k

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Aug 3, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	151,000	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2The holder undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $100.09 (range $99.44 to $100.43).
F4Open market sales reported on this line occurred at a weighted average price of $100.74 (range $100.47 to $101.37).
F5Open market sales reported on this line occurred at a weighted average price of $100.55 (range $100.00 to $100.99).
F6Open market sales reported on this line occurred at a weighted average price of $101.17 (range $101.00 to $101.50).
F7Fully vested.